Investigational Drug Information for LB1148
✉ Email this page to a colleague
What is the development status for investigational drug LB1148?
LB1148 is an investigational drug.
There have been 6 clinical trials for LB1148.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 28th 2022.
The most common disease conditions in clinical trials are Tissue Adhesions, Ileus, and Intestinal Diseases. The leading clinical trial sponsors are Leading BioSciences, Inc, Ronald Hurst, MD, FACS, and Newsoara Biopharma Co., Ltd.
There are three hundred and four US patents protecting this investigational drug and eleven international patents.
Summary for LB1148
| US Patents | 304 |
| International Patents | 11,416 |
| US Patent Applications | 3,093 |
| WIPO Patent Applications | 1,652 |
| Japanese Patent Applications | 1,811 |
| Clinical Trial Progress | Phase 2 (2022-06-28) |
| Vendors | 137 |
Recent Clinical Trials for LB1148
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection | Palisade Bio | Phase 3 |
| LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia | Leading BioSciences, Inc | Phase 2 |
| A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection | Leading BioSciences, Inc | Phase 2 |
Clinical Trial Summary for LB1148
Top disease conditions for LB1148
Top clinical trial sponsors for LB1148
US Patents for LB1148
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LB1148 | ⤷ Try a Trial | Phosphonate compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
| LB1148 | ⤷ Try a Trial | Use of GPR83 to identify pruritus-related substances | University of Miyazaki (Miyazaki, JP) | ⤷ Try a Trial |
| LB1148 | ⤷ Try a Trial | Double-acylated GLP-1 derivatives | Novo Nordisk A/S (Bagsvaerd, DK) | ⤷ Try a Trial |
| LB1148 | ⤷ Try a Trial | Derivatives of GLP-1 like peptides, and uses thereof | Novo Nordisk A/S (Bagsvaerd, DK) | ⤷ Try a Trial |
| LB1148 | ⤷ Try a Trial | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | Halozyme, Inc. (San Diego, CA) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LB1148
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LB1148 | Taiwan | TW201718611 | 2035-08-26 | ⤷ Try a Trial |
| LB1148 | World Intellectual Property Organization (WIPO) | WO2017035357 | 2035-08-26 | ⤷ Try a Trial |
| LB1148 | European Patent Office | EP2610619 | 2030-08-27 | ⤷ Try a Trial |
| LB1148 | Japan | JP5688718 | 2030-08-27 | ⤷ Try a Trial |
| LB1148 | Japan | JPWO2012026526 | 2030-08-27 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
